



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/56, 9/24, 15/86, 15/81, A61K 38/47</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/18861</p> <p>(43) International Publication Date: 13 July 1995 (13.07.95)</p>
<p>(21) International Application Number: PCT/BE95/00002</p> <p>(22) International Filing Date: 6 January 1995 (06.01.95)</p> <p>(30) Priority Data: 9400045 11 January 1994 (11.01.94) NL 94200159.5 24 January 1994 (24.01.94) EP (34) Countries for which the regional or international application was filed: AT et al.</p> <p>(71) Applicant (for all designated States except US): RIJKSUNIVERSITEIT GENT [BE/BE]; K.L. Ledeganckstraat 35, B-9000 Gent (BE).</p> <p>(71)(72) Applicant and Inventor: FIERS, Walter, Charles [BE/BE]; Beukendreef 3, B-9070 Destelbergen (BE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): DEROO, Tom, Maria [BE/BE]; Rijksweg 5, B-8520 Kuurne (BE). MIN JOU, Willy, Alfons [BE/BE]; Jagersstraat 11, B-9070 Destelbergen (BE).</p> <p>(74) Agent: LAND, Addick, Adrianus, Gosling; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).</p>		<p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published <i>With international search report. In English translation (filed in Dutch).</i></p>
<p>(54) Title: INFLUENZA VACCINE</p>		
<p>(57) Abstract</p> <p>The present invention relates to a recombinant neuraminidase to be obtained by culturing in a suitable culture medium host cells which are transformed with a neuraminidase expression vector or infected with a virus which is transformed with a neuraminidase expression vector, wherein the expression vector comprises at least a part of the coding region of a neuraminidase gene of an influenza virus minus the region which codes for the membrane anchor, or a modified version thereof, preceded in phase by a signal sequence; and isolating the expression product neuraminidase from the culture medium. The invention further relates to a vaccine in which the recombinant neuraminidase is applied, and methods for manufacturing and purifying thereof.</p>		